Table of Contents 1. Research Methodology 2. Executive Summary 3. Strategic Recommendations 4. Chemotherapy Drugs Market Outlook 5. Global Chemotherapy Drugs Market: Growth and Forecast 5.1 By Value (2013-2017) 5.2 By Value (2018-2023) 6. Global Chemotherapy Drugs Market: Segment Analysis 6.1 Global Antimetabolite Chemotherapy Drugs Market, By Value (2013-2023) 6.2 Global Plant Alkaloid Chemotherapy Drugs Market, By Value (2013-2023) 6.3 Global Antitumor Antibiotic Chemotherapy Drugs Market, By Value (2013-2023) 6.4 Other Chemotherapy Drugs Market, By Value (2013-2023) 6.5 Global Chemotherapy Drugs Market Size, By Route of Administration: Breakdown (%) 6.5.1 Global Chemotherapy Drugs Market Size, By Route of Administration, 2017 (%) 6.5.2 Global Chemotherapy Drugs Market Size, By Route of Administration, 2023 (%) 6.6 Global Intravenous Chemotherapy Drugs Market, By Value (2013-2023) 6.6 Global Oral Chemotherapy Drugs Market, By Value (2013-2023) 6.7 Other Chemotherapy Drugs Market, By Value (2013-2023) 7. Global Chemotherapy Drugs Market: Regional Analysis 7.1 Global Chemotherapy Drugs Market Size, By Region : Breakdown (%) 7.1.1 Global Chemotherapy Drugs Market Size, By Region, 2017 (%) 7.1.2 Global Chemotherapy Drugs Market Size, By Region, 2023 (%) 7.2 North America Chemotherapy Drugs Market: Growth and Forecast 7.2.1 By Value (2013-2017) 7.2.2 By Value (2018-2023) 7.2.3 By Type of Drug, By Value (2013-2017) 7.2.4 By Type of Drug, By Value (2018-2023) 7.2.5 By Route of Administration, By Value (2013-2017) 7.2.6 By Route of Administration, By Value (2018-2023) 7.3 North America Chemotherapy Drugs Market: Country Analysis (U.S and Canada) 7.3.1 U.S Chemotherapy Drugs Market, By Value (2013-2023) 7.3.2 Canada Chemotherapy Drugs Market, By Value (2013-2023) 7.4 Europe Chemotherapy Drugs Market: Growth and Forecast 7.4.1 By Value (2013-2017) 7.4.2 By Value (2018-2023) 7.4.3 By Type of Drug, By Value (2013-2017) 7.4.4 By Type of Drug, By Value (2018-2023) 7.4.5 By Route of Administration, By Value (2013-2017) 7.4.6 By Route of Administration, By Value (2018-2023) 7.5 Europe Chemotherapy Drugs Market: Country Analysis (Germany and U.K) 7.5.1 Germany Chemotherapy Drugs Market, By Value (2013-2023) 7.5.2 U.K Chemotherapy Drugs Market, By Value (2013-2023) 7.6 APAC Chemotherapy Drugs Market: Growth and Forecast 7.6.1 By Value (2013-2017) 7.6.2 By Value (2018-2023) 7.6.3 By Type of Drug, By Value (2013-2017) 7.6.4 By Type of Drug, By Value (2018-2023) 7.6.5 By Route of Administration, By Value (2013-2017) 7.6.6 By Route of Administration, By Value (2018-2023) 7.7 APAC Chemotherapy Drugs Market: Country Analysis (India and China) 7.7.1 India Chemotherapy Drugs Market, By Value (2013-2023) 7.7.2 China Chemotherapy Drugs Market, By Value (2013-2023) 7.8 ROW Chemotherapy Drugs Market: Growth and Forecast 7.8.1 By Value (2013-2017) 7.8.2 By Value (2018-2023) 7.8.3 By Type of Drug, By Value (2013-2017) 7.8.4 By Type of Drug, By Value (2018-2023) 7.8.5 By Route of Administration, By Value (2013-2017) 7.8.6 By Route of Administration, By Value (2018-2023) 8. Global Chemotherapy Drugs Market Dynamics 8.1 Global Chemotherapy Drugs Market Drivers 8.2 Global Chemotherapy Drugs Market Restraints 9. Global Chemotherapy Drugs Market Trends 10. Porter Five Force Analysis 11. SWOT Analysis 12. Policy and Regulatory Landscape 14. Company Profiles 14.1 Pfizer 14.2 Eli Lilly & Company 14.3 CELGENE Corporation 14.4 Bristol-Myers Squibb 14.5 Merck & Co., Inc. 14.6 GlaxoSmithKline plc 14.7 Novartis 14.8 Sanofi 14.9 Teva Pharmaceuticals Industries Limited

List of Figures Figure 1: Common Treatment Modalities for Cancer Figure 2: Cancer Treatment Flowchart Figure 3: Chemotherapy Drugs Market Segmentation Flowchart Figure 4: Global Chemotherapy Drugs Market Size, By Value, 2013-2017 (USD Million) Figure 5: Global Chemotherapy Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million) Figure 6: Key factors driving of change in the global oncology market Figure 7: Projected global population (In Billions) Figure 8: Population ages 65 and above, By Select Region, 2013-2017 (% of total) Figure 9: Projected global population aged 60 years & above (In Billions) Figure 10: Global Health Expenditure Per Capita, By Select Countries, 2016 (In USD) Figure 11: Global Health Expenditure Per Capita, (2012-2016, USD Trillion) Figure 12: Global Burden of Cancer Figure 13: Prevalence and Epidemiology of Cancer Worldwide Figure 14: 5 Year Survival Rate, Breast and Colorectal Cancer Figure 15: Types of cancer for which clinical trials using chemotherapy drugs treatment are being conducted Figure 16: Global Prevalence of Different Type of Cancer, 2017 (In Thousands) Figure 17: Global Prevalence of Prostate Cancer (2013-2017, Thousands) Figure 18: Oncologists per 1 Million of Population, By Select Country, 2018 Figure 19: Availability of New Cancer Drugs Launched in 2012-2016, By Select Country (As of 2017) Figure 20: Global Antimetabolite Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million) Figure 21: Global Antimetabolite Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million) Figure 22: Global Plant Alkaloid Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million) Figure 23: Global Plant Alkaloid Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million) Figure 24: Global Alkylating Agent Drugs Market, By Value, 2013-2017 (USD Million) Figure 25: Global Alkylating Agent Drugs Market, By Value, Forecast, 2018-2023 (USD Million) Figure 26: Global Anti-tumor Antibiotic Drugs Market, By Value, 2013-2017 (USD Million) Figure 27: Global Anti-tumor Antibiotic Drugs Market, By Value, Forecast, 2018-2023 (USD Million) Figure 28: Other Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million) Figure 29: Other Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million) Figure 30: Global Chemotherapy Drugs Market Size, By Route of Administration, 2017 (%) Figure 31: Global Chemotherapy Drugs Market Size,By Route of Administration, 2023 (%) Figure 32: Global Intravenous Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million) Figure 33: Global Intravenous Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million) Figure 34: Global Oral Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million) Figure 35: Global Oral Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million) Figure 36: Other Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million) Figure 37: Other Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million) Figure 38: Global Chemotherapy Drugs Market Size, By Region, 2017 (%) Figure 39: Global Chemotherapy Drugs Market Size, By Region, 2023 (%) Figure 40: North America Chemotherapy Drugs Market Size, By Value, 2013-2017 (USD Million) Figure 41: North America Chemotherapy Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million) Figure 42: North America GDP, 2012-2017 (USD Trillion) Figure 43: North America GDP per capita, current prices, 2013-2023F (In USD) Figure 44: Prevalence of Different Type of Cancer in North America in year 2016 & 2017 ( In Hundreds) Figure 45: North America, Cancer Incidence (In Millions) Figure 46: North America, Cancer Incidence, By Route of Administration, 2019E (In %) Figure 47: North America Population above 65 year, 2015, 2030F, & 2050F (In Millions) Figure 48: North America Chemotherapy Drugs Market: By Type of Drug, By Value, 2013-2017 (USD Million) Figure 49: North America Chemotherapy Drugs Market: By Type of Drug, By Value, 2018E-2023F (USD Million) Figure 50: North America Chemotherapy Drugs Market: By Route of Administration, By Value, 2013-2017 (USD Million) Figure 51: North America Chemotherapy Drugs Market: By Route of Administration, By Value, 2018E-2023F (USD Million) Figure 52: U.S. Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million) Figure 53: Leading Sites of New Cancer Cases in the United States amongst Males, 2018 (In %) Figure 54: Leading Sites of New Cancer Cases in the United States amongst Males, 2018 (In %) Figure 55: Leading Sites of New Cancer Cases in the United States amongst Males, 2018 (In %) Figure 56: Estimated New Cases of Cancer in the United States, 2014-2018 (In Thousands) Figure 57: Estimated New Cases of Cancer in the United States, By State, 2018 Figure 58: Estimated Numbers of US Cancer Survivors (As of January 1, 2016) Figure 59: Estimated Numbers of US Cancer Survivors (As of January 1, 2026F) Figure 60: Factors Influencing Patient Out-of-Pocket Costs for Cancer Medicines Figure 61: United States, Top Players in the chemotherapy drugs market, By Company Share, 2017 (%) Figure 62: Canada Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million) Figure 63: Cancer Burden in Canada, 2017 Figure 64: Prevalence of Different Type of Cancer in Canada, 2016 & 2017 ( In Hundreds) Figure 65: Cancer Fact Sheet of Canada, 2017 Figure 66: Canada, Expenditure on Health as a share of GDP, 2012-2017 (In %) Figure 67: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD) Figure 68: North America Chemotherapy Drugs Market, Country Share, 2013-2017 (% of Total) Figure 69: North America Chemotherapy Drugs Market, Country Share, 2018F-2023F (% of Total) Figure 70: Europe Chemotherapy Drugs Market Size, By Value, 2013-2017 (USD Million) Figure 71: Europe Chemotherapy Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million) Figure 72: Europe, Cancer Incidence, 2019E-2035F (In Millions) Figure 73: Europe, Cancer Incidence, By Type, 2019E Figure 74: Prevalence of Different Type of Cancer in Western Europe in year 2016 & 2017 ( In Thousands) Figure 75: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD) Figure 76: GDP, Europe Region, By Select Country, 2017 (In Trillion USD) Figure 77: Breakdown of Total Health Expenditure in Europe, 2018 (%) Figure 78: Major Players in Chemotherapy Drugs Market in Europe Figure 79: Europe Chemotherapy Drugs Market: By Type of Drug, By Value, 2013-2017 (USD Million) Figure 80: Europe Chemotherapy Drugs Market: By Type of Drug, By Value, 2018E-2023F (USD Million) Figure 81: Europe Chemotherapy Drugs Market: By Route of Administration, By Value, 2013-2017 (USD Million) Figure 82: Europe Chemotherapy Drugs Market: By Route of Administration, By Value, 2018E-2023F (USD Million) Figure 83: Germany Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million) Figure 84: Germany, Health Expenditure Per Capita, PPP, 2012-2017 (USD) Figure 85: Prevalence of Different Type of Cancer in Germany in year 2016 & 2017 ( In Hundreds) Figure 86: U.K Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million) Figure 87: Cancer Statistics in the United Kingdom Figure 88: U.K, Health Expenditure Per Capita, PPP, 2012-2017 (USD) Figure 89: Europe Chemotherapy Drugs Market, Country Share, Historic, 2013-2017(% of Total) Figure 90: Europe Chemotherapy Drugs Market, Country Share, Forecast, 2018-2023 (% of Total) Figure 91: APAC Chemotherapy Drugs Market Size, By Value, 2013-2017 (USD Million) Figure 92: APAC Chemotherapy Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million) Figure 93: Estimated number of deaths from prostate cancer in 2012 and 2030 Figure 94: World health expenditure as % of GDP Figure 95: Population ages 65 and above, APAC Region, By Select Countries, 2017 (% of total) Figure 96: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total) Figure 97: APAC, GDP, By Select Country, 2017 (In USD Trillion) Figure 98: APAC Chemotherapy Drugs Market: By Type of Drug, By Value, 2013-2017 (USD Million) Figure 99: APAC Chemotherapy Drugs Market: By Type of Drug, By Value, 2018E-2023F (USD Million) Figure 100: APAC Chemotherapy Drugs Market: By Route of Administration, By Value, 2013-2017 (USD Million) Figure 101: APAC Chemotherapy Drugs Market: By Route of Administration, By Value, 2018E-2023F (USD Million) Figure 102: India Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million) Figure 103: Key factors affecting the Indian Healthcare Industry Figure 104: India, Total Population, 2013-2023F (In Billion) Figure 105: India, Share of Urban Population, 2012-2017 (In %) Figure 106: India, GDP Growth Per Year, 2015-2019 (In %) Figure 107: India, Total deaths due to cancer, 2018 Figure 108: Top 5 forms of cancer in men and women in India Figure 109: China Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million) Figure 110: China, GDP Growth Per Year, 2015-2019 (In %) Figure 111: China, Share of Urban Population, 2012-2017 (In %) Figure 112: China, Total Population, 2013-2021F (In Billion) Figure 113: Prevalence of Different Type of Cancer in China in year 2016 & 2017 ( In Hundreds) Figure 114: Number of new cases, Males (all ages), 2018 (In %) Figure 115: Number of new cases, Females (all ages), 2018 (In %) Figure 116: China, Cancer Mortality Rate, By Cancer Site, 2018 Figure 117: APAC Chemotherapy Drugs Market, Country Share, Historic, 2013-2017 (% of Total) Figure 118: APAC Chemotherapy Drugs Market, Country Share, Forecast, 2018-2023 (% of Total) Figure 119: ROW Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million) Figure 120: Middle East and North Africa, GDP, 2012-2017 (In USD Trillion) Figure 121: Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2017 (In %) Figure 122: Prevalence of Different Type of Cancer in Middle East and North Africa in year 2016 & 2017 ( In Hundreds) Figure 123: Prevalence of Different Type of Cancer in Brazil in year 2016 & 2017 ( In Hundreds) Figure 124: ROW Chemotherapy Drugs Market: By Type of Drug, By Value, 2013-2017 (USD Million) Figure 125: ROW Chemotherapy Drugs Market: By Type of Drug, By Value, 2018E-2023F (USD Million) Figure 126: ROW Chemotherapy Drugs Market: By Route of Administration, By Value, 2013-2017 (USD Million) Figure 127: ROW Chemotherapy Drugs Market: By Route of Administration, By Value, 2018E-2023F (USD Million) Figure 128: Drug Discovery and Development, Approximate Timeline Figure 129: Pfizer, Revenue, 2013-2017 (In USD Billion) Figure 130: Pfizer, Revenue, By Business Segment, 2017 (In %) Figure 131: Pfizer, Revenue, By National Market, 2015-2017 (In %) Figure 132: Pfizer, Oncology Revenue, 2015-2017 (In USD Million) Figure 133: Eli Lilly & Company, Revenue, 2013-2017 (In USD Billion) Figure 134: Eli Lilly & Company, Revenue, By Business Segment, 2017 (In %) Figure 135: Eli Lilly & Company, Net Sales, By Geographic Region, 2017 (In %) Figure 136: CELGENE Corporation, Revenue, 2013-2017 (In USD Million) Figure 137: CELGENE Corporation, Net Sales, By Geographic Region, 2017 (In %) Figure 138: Bristol-Myers Squibb, Revenue, 2013-2017 (In USD Million) Figure 139: Bristol-Myers Squibb, Revenue, By Business Segment, 2017 (In %) Figure 140: Bristol-Myers Squibb, Net Sales, By Geographic Region, 2017 (In %) Figure 141: Merck & Co., Inc., Revenue, 2013-2017 (In USD Million) Figure 142: Merck & Co., Inc., Net Sales, By Geographic Region, 2017 (In %) Figure 143: GlaxoSmithKline plc, Revenue, 2013-2017 (In USD Million) Figure 144: GlaxoSmithKline plc, Revenue, By Business Segment, 2017 (In %) Figure 145: GlaxoSmithKline plc, Net Sales, By Geographic Region, 2017 (In %) Figure 146: Novartis, Revenue, 2014-2018 (In USD Million) Figure 147: Novartis, Net Sales, By Business Segment, 2017 (In %) Figure 148: Sanofi, Revenue, 2013-2017 (In USD Million) Figure 149: Sanofi , Revenue, By Business Segment, 2017 (In %) Figure 150: Sanofi, Net Sales, By Geographic Region, 2017 (In %) Figure 151: Teva Pharmaceutical INDUSTRIES LIMITED, Revenue, 2013-2017 (In USD Million) Figure 152: Teva Pharmaceutical INDUSTRIES LIMITED, Revenue, By Business Segment, 2017 (In %) Figure 153: Teva Pharmaceutical INDUSTRIES LIMITED, Net Sales, By Geographic Region, 2017 (In %) List of Tables Table A: Approach and Limitations of Common Treatment Modalities for Cancer Table B: Recent Company Acquisitions and Mergers in Chemotherapy Drugs Market Table C: Germany, Healthcare Related Statistics, 2017 Table D: Estimated number of people living with cancer, 2020F and 2030F Table E: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10) Table F: India, Cancer Statistics

fizer, Eli Lilly & Company, Celgene Corporation, Bristol-Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc, Novartis, Sanofi, Teva Pharmaceutical Industries Limited.